OBJECTIVES: To determine incidence, related factors, outcome, bacterial organisms and their sensitivity patterns with regard to ventilator-associated pneumonia (VAP) in children. SETTING: Level III PICU of a tertiary care center. DESIGN: Prospective cohort study. METHODS: Children in the age group of 1 month to 15 years, admitted to the pediatric intensive care unit requiring ventilatory support (V.I.P.BIRD infant-Pediatric ventilator) for at least 48 h. Clinical criteria used to define VAPs were the same as used by and Elward et al. and Salata et al. RESULTS: Forty patients met the inclusion criteria and 8 (20%) had VAP. The risk factor significantly related with development of VAP was the use of H(2) blockers (Ranitidine) for >2 days. All other related factors were not significantly related to occurrence of VAP. CONCLUSION: Use of H(2) blockers (Ranitidne) is associated with higher incidence of VAP in children.
OBJECTIVES: To determine incidence, related factors, outcome, bacterial organisms and their sensitivity patterns with regard to ventilator-associated pneumonia (VAP) in children. SETTING: Level III PICU of a tertiary care center. DESIGN: Prospective cohort study. METHODS:Children in the age group of 1 month to 15 years, admitted to the pediatric intensive care unit requiring ventilatory support (V.I.P.BIRD infant-Pediatric ventilator) for at least 48 h. Clinical criteria used to define VAPs were the same as used by and Elward et al. and Salata et al. RESULTS: Forty patients met the inclusion criteria and 8 (20%) had VAP. The risk factor significantly related with development of VAP was the use of H(2) blockers (Ranitidine) for >2 days. All other related factors were not significantly related to occurrence of VAP. CONCLUSION: Use of H(2) blockers (Ranitidne) is associated with higher incidence of VAP in children.
Authors: Edward I Broughton; Sergio R López; María Nela Aguilar; María Mercedes Somarriba; Magaly Pérez; Nieves Sánchez Journal: Int J Pediatr Date: 2012-02-08